AU2015261536B2 - Improved immunoglobulin variable domains - Google Patents

Improved immunoglobulin variable domains Download PDF

Info

Publication number
AU2015261536B2
AU2015261536B2 AU2015261536A AU2015261536A AU2015261536B2 AU 2015261536 B2 AU2015261536 B2 AU 2015261536B2 AU 2015261536 A AU2015261536 A AU 2015261536A AU 2015261536 A AU2015261536 A AU 2015261536A AU 2015261536 B2 AU2015261536 B2 AU 2015261536B2
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid residue
nanobody
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015261536A
Other languages
English (en)
Other versions
AU2015261536A1 (en
Inventor
Carlo Boutton
Marie-Ange Buyse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of AU2015261536A1 publication Critical patent/AU2015261536A1/en
Priority to AU2018204226A priority Critical patent/AU2018204226A1/en
Priority to AU2020202570A priority patent/AU2020202570B2/en
Priority to AU2020202855A priority patent/AU2020202855B2/en
Application granted granted Critical
Publication of AU2015261536B2 publication Critical patent/AU2015261536B2/en
Priority to AU2022279373A priority patent/AU2022279373A1/en
Priority to AU2022279374A priority patent/AU2022279374A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2015261536A 2014-05-16 2015-05-13 Improved immunoglobulin variable domains Active AU2015261536B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2018204226A AU2018204226A1 (en) 2014-05-16 2018-06-14 Improved immunoglobulin variable domains
AU2020202570A AU2020202570B2 (en) 2014-05-16 2020-04-16 Improved immunoglobulin variable domains
AU2020202855A AU2020202855B2 (en) 2014-05-16 2020-04-30 Improved immunoglobulin variable domains
AU2022279373A AU2022279373A1 (en) 2014-05-16 2022-11-28 Improved immunoglobulin variable domains
AU2022279374A AU2022279374A1 (en) 2014-05-16 2022-11-28 Improved immunoglobulin variable domains

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US61/994,552 2014-05-16
US201462014015P 2014-06-18 2014-06-18
US201461014015P 2014-06-18 2014-06-18
US62/014,015 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US62/040,167 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US62/047,560 2014-09-08
US201562133600P 2015-03-16 2015-03-16
US62/133,600 2015-03-16
PCT/EP2015/060643 WO2015173325A2 (en) 2014-05-16 2015-05-13 Improved immunoglobulin variable domains

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2018204226A Division AU2018204226A1 (en) 2014-05-16 2018-06-14 Improved immunoglobulin variable domains
AU2020202855A Division AU2020202855B2 (en) 2014-05-16 2020-04-30 Improved immunoglobulin variable domains

Publications (2)

Publication Number Publication Date
AU2015261536A1 AU2015261536A1 (en) 2016-11-17
AU2015261536B2 true AU2015261536B2 (en) 2020-05-07

Family

ID=91193230

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2015261536A Active AU2015261536B2 (en) 2014-05-16 2015-05-13 Improved immunoglobulin variable domains
AU2018204226A Abandoned AU2018204226A1 (en) 2014-05-16 2018-06-14 Improved immunoglobulin variable domains
AU2020202570A Active AU2020202570B2 (en) 2014-05-16 2020-04-16 Improved immunoglobulin variable domains
AU2020202855A Active AU2020202855B2 (en) 2014-05-16 2020-04-30 Improved immunoglobulin variable domains
AU2022279374A Pending AU2022279374A1 (en) 2014-05-16 2022-11-28 Improved immunoglobulin variable domains
AU2022279373A Pending AU2022279373A1 (en) 2014-05-16 2022-11-28 Improved immunoglobulin variable domains

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2018204226A Abandoned AU2018204226A1 (en) 2014-05-16 2018-06-14 Improved immunoglobulin variable domains
AU2020202570A Active AU2020202570B2 (en) 2014-05-16 2020-04-16 Improved immunoglobulin variable domains
AU2020202855A Active AU2020202855B2 (en) 2014-05-16 2020-04-30 Improved immunoglobulin variable domains
AU2022279374A Pending AU2022279374A1 (en) 2014-05-16 2022-11-28 Improved immunoglobulin variable domains
AU2022279373A Pending AU2022279373A1 (en) 2014-05-16 2022-11-28 Improved immunoglobulin variable domains

Country Status (25)

Country Link
US (10) US12180268B2 (cg-RX-API-DMAC7.html)
EP (4) EP3143042B1 (cg-RX-API-DMAC7.html)
JP (6) JP7325928B2 (cg-RX-API-DMAC7.html)
KR (5) KR20230145503A (cg-RX-API-DMAC7.html)
CN (3) CN109053885A (cg-RX-API-DMAC7.html)
AU (6) AU2015261536B2 (cg-RX-API-DMAC7.html)
BR (2) BR122018009619B1 (cg-RX-API-DMAC7.html)
CA (2) CA2948076A1 (cg-RX-API-DMAC7.html)
DK (2) DK3248986T3 (cg-RX-API-DMAC7.html)
ES (2) ES2912069T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20200966T1 (cg-RX-API-DMAC7.html)
HU (2) HUE058008T2 (cg-RX-API-DMAC7.html)
IL (6) IL299282B2 (cg-RX-API-DMAC7.html)
LT (2) LT3143042T (cg-RX-API-DMAC7.html)
MX (4) MX383560B (cg-RX-API-DMAC7.html)
NZ (1) NZ726448A (cg-RX-API-DMAC7.html)
PH (1) PH12016502282B1 (cg-RX-API-DMAC7.html)
PL (2) PL3143042T3 (cg-RX-API-DMAC7.html)
PT (2) PT3143042T (cg-RX-API-DMAC7.html)
RS (2) RS63085B1 (cg-RX-API-DMAC7.html)
RU (1) RU2746738C2 (cg-RX-API-DMAC7.html)
SG (3) SG11201609162SA (cg-RX-API-DMAC7.html)
SI (2) SI3248986T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015173325A2 (cg-RX-API-DMAC7.html)
ZA (5) ZA201607587B (cg-RX-API-DMAC7.html)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
RS63085B1 (sr) * 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
EP3247407A4 (en) 2015-01-21 2018-08-22 Inhibrx LP Non-immunogenic single domain antibodies
NO2768984T3 (cg-RX-API-DMAC7.html) 2015-11-12 2018-06-09
JP7403224B2 (ja) 2015-11-12 2023-12-22 アブリンクス エン．ヴェー． 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド
PL3374392T3 (pl) 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
GEP20207174B (en) 2015-11-18 2020-11-10 Merck Sharp & Dohme Ctla4 binders
WO2017087587A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
US11332519B2 (en) * 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
US10975141B2 (en) 2016-02-12 2021-04-13 Ablynx N.V. Method for the production of immunoglobulin single variable domains
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
JP7150618B2 (ja) 2016-06-23 2022-10-11 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインについての改善された薬物動態アッセイ
IL266506B2 (en) 2016-11-16 2025-05-01 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
DK3571225T3 (da) 2017-01-17 2024-11-04 Ablynx Nv Forbedrede serumalbuminbindere
WO2018134234A1 (en) 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
US11261260B2 (en) 2017-06-02 2022-03-01 Merck Patent Gmbh ADAMTS binding immunoglobulins
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw AGENTS FOR CONNECTING TO SERUM ALBUMIN
EP3704160B1 (en) 2017-10-31 2025-08-20 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
CN113710229A (zh) 2019-02-25 2021-11-26 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
EP3962599A1 (en) 2019-04-30 2022-03-09 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
WO2021110817A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
PH12022551214A1 (en) * 2019-12-06 2023-10-09 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnf# and il-23
WO2021116182A1 (en) 2019-12-09 2021-06-17 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CA3165429A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
WO2021170540A1 (en) 2020-02-25 2021-09-02 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
MX2022012278A (es) 2020-03-30 2022-10-27 Ablynx Nv Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
US20230272094A1 (en) * 2020-08-05 2023-08-31 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
AU2021402090A1 (en) 2020-12-18 2023-08-03 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
IL304929A (en) 2021-02-05 2023-10-01 Vib Vzw [Be/Be Sarbecovirus binders
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022206900A1 (zh) * 2021-04-01 2022-10-06 江苏先声药业有限公司 抗人血清白蛋白(hsa)的纳米抗体及其应用
JP2024530455A (ja) 2021-07-30 2024-08-21 ブイアイビー ブイゼットダブリュ 標的化タンパク質の分解のためのカチオン非依存性マンノース６リン酸受容体結合体
JP2024543134A (ja) * 2021-11-29 2024-11-19 江蘇恒瑞医薬股▲ふん▼有限公司 修飾されたタンパク質又はポリペプチド
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
CA3248241A1 (en) 2022-01-12 2023-07-20 Vib Vzw HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND TARGETED LIVER ADMINISTRATION
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
IL316376A (en) 2022-05-06 2024-12-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
AU2023273998A1 (en) 2022-05-18 2024-11-14 Exevir Bio Bv Sarbecovirus spike s2 subunit binders
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
IL317588A (en) 2022-06-14 2025-02-01 Ablynx Nv Single immunoglobulin variable sites targeting the T cell receptor
KR20250042176A (ko) 2022-07-27 2025-03-26 아블린쓰 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
AU2023409104A1 (en) 2022-12-21 2025-07-31 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
WO2024168279A2 (en) 2023-02-10 2024-08-15 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
AU2024234615A1 (en) 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024231447A1 (en) 2023-05-08 2024-11-14 Sanofi Glycosylation of immunoglobulin single variable domains
AU2024273077A1 (en) 2023-05-17 2025-11-13 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
TW202515917A (zh) 2023-06-29 2025-04-16 美商奧迪希治療公司 抗trailr2抗原結合蛋白及其用途
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074780A1 (en) * 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2012175741A2 (en) * 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) * 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4996206A (en) 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5248775A (en) 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US7943129B2 (en) * 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AU2002360243A1 (en) 2001-07-26 2003-05-06 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CN103254309B (zh) * 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
US7989219B2 (en) 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007063311A2 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
EP2152747B1 (en) 2007-05-24 2018-01-03 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EA018471B1 (ru) 2008-03-31 2013-08-30 Глаксо Груп Лимитед Слитые конструкции и конъюгаты лекарственного средства
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
BRPI0911984A2 (pt) 2008-05-16 2016-09-20 Ablynx Nv sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110200525A1 (en) 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
KR20110137819A (ko) 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
EP2982690B1 (en) 2009-04-30 2021-01-27 Ablynx N.V. Method for the production of domain antibodies
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
CN102458471A (zh) 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
EP2486056A1 (en) 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
US8962807B2 (en) * 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
JP5914353B2 (ja) * 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
JP2013525408A (ja) 2010-04-30 2013-06-20 アブリンクス エン．ヴェー． ヘテロ二量体サイトカインｉｌ−２３のｐ１９サブユニットに指向性を有するナノボディのアミノ酸配列
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN106046168A (zh) * 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
US20130019175A1 (en) 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
UA118833C2 (uk) * 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
JP6219287B2 (ja) 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
KR20250021626A (ko) 2011-10-17 2025-02-13 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
RS58439B1 (sr) * 2012-01-31 2019-04-30 Regeneron Pharma Anti-asic1 antitela i njihove upotrebe
WO2013178783A1 (en) 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
WO2014043509A2 (en) * 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
BR112018008754A2 (pt) 2015-10-30 2018-10-30 Ablynx Nv polipeptídeo contra il-23
JP7403224B2 (ja) 2015-11-12 2023-12-22 アブリンクス エン．ヴェー． 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド
NO2768984T3 (cg-RX-API-DMAC7.html) 2015-11-12 2018-06-09
PL3374392T3 (pl) 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
US11332519B2 (en) 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
WO2017087587A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
GEP20207174B (en) 2015-11-18 2020-11-10 Merck Sharp & Dohme Ctla4 binders
WO2018134234A1 (en) 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
PH12022551214A1 (en) 2019-12-06 2023-10-09 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnf# and il-23
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074780A1 (en) * 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2012175741A2 (en) * 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Also Published As

Publication number Publication date
US20210261653A1 (en) 2021-08-26
ZA202004757B (en) 2022-08-31
IL299282B2 (en) 2024-09-01
US11220539B2 (en) 2022-01-11
WO2015173325A2 (en) 2015-11-19
PT3248986T (pt) 2022-04-05
RS60717B1 (sr) 2020-09-30
PL3248986T3 (pl) 2022-05-16
US20210269515A1 (en) 2021-09-02
US20170121399A1 (en) 2017-05-04
WO2015173325A8 (en) 2016-12-29
EP3248986A2 (en) 2017-11-29
IL295534B2 (en) 2025-03-01
JP7454525B2 (ja) 2024-03-22
JP2021130681A (ja) 2021-09-09
BR122018009619B1 (pt) 2024-01-02
SG10201805288QA (en) 2018-07-30
MX2021007020A (es) 2021-08-05
AU2020202570B2 (en) 2022-12-08
DK3248986T3 (da) 2022-04-04
US20220119512A1 (en) 2022-04-21
ZA202004759B (en) 2022-08-31
IL311293B1 (en) 2025-03-01
JP2018162297A (ja) 2018-10-18
PH12016502282A1 (en) 2017-02-13
IL281755B2 (en) 2023-05-01
KR102769509B1 (ko) 2025-02-17
PT3143042T (pt) 2020-09-01
AU2020202855B2 (en) 2022-12-08
RU2016149463A3 (cg-RX-API-DMAC7.html) 2018-07-04
JP7471987B2 (ja) 2024-04-22
RU2016149463A (ru) 2018-06-19
DK3143042T3 (da) 2020-08-31
RU2746738C2 (ru) 2021-04-20
KR20230053002A (ko) 2023-04-20
US20220251183A1 (en) 2022-08-11
AU2020202855A1 (en) 2020-05-21
IL299282B1 (en) 2024-05-01
CN113717280A (zh) 2021-11-30
IL259972A (en) 2018-07-31
AU2022279373A1 (en) 2023-01-19
RU2018120744A3 (cg-RX-API-DMAC7.html) 2022-01-28
RU2021107470A (ru) 2021-05-17
MX383560B (es) 2025-03-14
US11319364B2 (en) 2022-05-03
US11485777B2 (en) 2022-11-01
JP2024069377A (ja) 2024-05-21
CN109053885A (zh) 2018-12-21
LT3248986T (lt) 2022-03-25
AU2015261536A1 (en) 2016-11-17
MX2016014926A (es) 2017-05-09
NZ726448A (en) 2023-02-24
US20200231662A1 (en) 2020-07-23
AU2022279374A1 (en) 2023-01-19
EP3143042A2 (en) 2017-03-22
LT3143042T (lt) 2020-07-27
EP3693386A1 (en) 2020-08-12
US20210087261A1 (en) 2021-03-25
EP3248986A3 (en) 2017-12-20
CN106661100A (zh) 2017-05-10
EP3248986B1 (en) 2022-01-26
IL311293A (en) 2024-05-01
JP2024041939A (ja) 2024-03-27
IL281755B1 (en) 2023-01-01
IL259972B (en) 2021-04-29
CA3175002A1 (en) 2015-11-19
EP3702369A1 (en) 2020-09-02
HUE058008T2 (hu) 2022-06-28
KR20180091115A (ko) 2018-08-14
SI3143042T1 (sl) 2020-08-31
KR20230054503A (ko) 2023-04-24
IL295534A (en) 2022-10-01
US20220332807A1 (en) 2022-10-20
US11312765B2 (en) 2022-04-26
IL299282A (en) 2023-02-01
KR20230145503A (ko) 2023-10-17
JP2017518072A (ja) 2017-07-06
MX2018007581A (es) 2020-11-12
EP3143042B1 (en) 2020-06-10
AU2018204226A1 (en) 2018-07-05
BR112016026773A2 (pt) 2017-12-12
KR20170002645A (ko) 2017-01-06
US12180268B2 (en) 2024-12-31
HUE050007T2 (hu) 2020-11-30
ES2912069T3 (es) 2022-05-24
PL3143042T3 (pl) 2020-11-16
WO2015173325A3 (en) 2016-02-18
US20220332806A1 (en) 2022-10-20
US20220135657A9 (en) 2022-05-05
IL295534B1 (en) 2024-11-01
SG10201810124PA (en) 2018-12-28
JP7098439B2 (ja) 2022-07-11
JP2021006563A (ja) 2021-01-21
JP7325928B2 (ja) 2023-08-15
ZA201607587B (en) 2022-05-25
MX2023010731A (es) 2023-09-20
HRP20220400T1 (hr) 2022-05-27
ES2815572T3 (es) 2021-03-30
US11485778B2 (en) 2022-11-01
SG11201609162SA (en) 2016-12-29
US20210269514A1 (en) 2021-09-02
SI3248986T1 (sl) 2022-04-29
US11708404B2 (en) 2023-07-25
ZA202004758B (en) 2022-08-31
KR102827683B1 (ko) 2025-06-30
CA2948076A1 (en) 2015-11-19
IL281755A (en) 2021-05-31
US11312764B2 (en) 2022-04-26
RU2018120744A (ru) 2018-11-15
RS63085B1 (sr) 2022-04-29
HRP20200966T1 (hr) 2020-10-16
ZA202100742B (en) 2022-09-28
AU2020202570A1 (en) 2020-05-07
IL248636A0 (en) 2017-01-31
IL248636B (en) 2022-12-01
PH12016502282B1 (en) 2024-05-22
IL311293B2 (en) 2025-07-01
IL248636B2 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
AU2015261536B2 (en) Improved immunoglobulin variable domains
USRE50682E1 (en) Immunoglobulin variable domains
HK40035363A (en) Immunoglobulin variable domains
HK40033677A (en) Immunoglobulin variable domains

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 61/994,552 16 MAY 2014 US; 62/014,015 18 JUN 2014 US; 62/133,600 16 MAR 2015 US; 62/040,167 21 AUG 2014 US AND 62/047,560 08 SEP 2014 US

FGA Letters patent sealed or granted (standard patent)